Literature DB >> 17005397

No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy.

E L van der Kooi1, J C de Greef, M Wohlgemuth, R R Frants, R J G P van Asseldonk, H J Blom, B G M van Engelen, S M van der Maarel, G W Padberg.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is associated with a contraction of the D4Z4 allele on chromosome 4qter. There is also marked DNA hypomethylation of the D4Z4 allele. The DNA hypomethylation may have a central role in the pathogenesis of FSHD. Supplemental folic acid can boost DNA methylation. We evaluated the effect of oral folic acid and methionine supplementation on the methylation level of 4qter D4Z4 alleles in peripheral-blood lymphocytes of nine patients affected with FSHD and six healthy controls. Methylation levels did not change, while recommended serum-folate concentrations were reached.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005397     DOI: 10.1016/j.nmd.2006.08.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  13 in total

1.  Epigenetics in congenital diseases and pervasive developmental disorders.

Authors:  Takeo Kubota
Journal:  Environ Health Prev Med       Date:  2007-12-11       Impact factor: 3.674

Review 2.  FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?

Authors:  Charis L Himeda; Peter L Jones
Journal:  J Pers Med       Date:  2022-05-25

Review 3.  Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.

Authors:  Justin Cohen; Alec DeSimone; Monkol Lek; Angela Lek
Journal:  Trends Mol Med       Date:  2020-10-19       Impact factor: 11.951

Review 4.  Facioscapulohumeral muscular dystrophy.

Authors:  Rabi Tawil
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 5.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.

Authors:  Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

Review 6.  Current Therapeutic Approaches in FSHD.

Authors:  Leo H Wang; Rabi Tawil
Journal:  J Neuromuscul Dis       Date:  2021

Review 7.  Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals.

Authors:  Ceren Hangül; Sibel Berker Karaüzüm; Esra Küpeli Akkol; Devrim Demir-Dora; Zafer Çetin; Eyüp İlker Saygılı; Gökhan Evcili; Eduardo Sobarzo-Sánchez
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 8.  Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature.

Authors:  Adam Philip Denny; Alison Kay Heather
Journal:  Oxid Med Cell Longev       Date:  2017-06-12       Impact factor: 6.543

9.  A Two-DNA Methylation Signature to Improve Prognosis Prediction of Clear Cell Renal Cell Carcinoma.

Authors:  Shanping Shi; Shazhou Ye; Xiaoyue Wu; Mingjun Xu; Renjie Zhuo; Qi Liao; Yang Xi
Journal:  Yonsei Med J       Date:  2019-11       Impact factor: 2.759

Review 10.  Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.

Authors:  Teresa Schätzl; Lars Kaiser; Hans-Peter Deigner
Journal:  Orphanet J Rare Dis       Date:  2021-03-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.